One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

President Trump reportedly held a “fiery” call with Denmark’s Prime Minister Mette Frederiksen over the president’s insistence that U.S. control of Greenland is necessary for American ...

was $540 now $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

and choosing the optimal meals for weight loss can be challenging. A research team has developed a weight management program that helps individuals plan meals with the assistance of a web ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

As Alzheimer’s disease is the most common form of dementia — affecting an estimated 6.7 million Americans — it’s not surprising that people who experience memory loss may suspect AD.

One year later, they did just that. Notre Dame showed enough growth since a shocking loss in September to Northern Illinois to supports the team’s confidence that the national championship could ...

Healthcare & Pharmaceuticalscategory Outgoing FDA chief flags online weight loss drug dangers January 17, 2025 Healthcare & Pharmaceuticalscategory Novo Nordisk says its obesity drug in higher ...